TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11403352

Group type: EXPERIMENTAL
Intervention: 25 weeks of exercise training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control program
Number of subjects: 39
Study: 9513907

Group type: EXPERIMENTAL
Intervention: Methylprednisolone plus chlorambucil
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Methylprednisolone plus cyclophosphamide
Number of subjects: 87

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 87
Study: 8139992

Group type: EXPERIMENTAL
Intervention: Optimal AV delay (100-250 msec)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Most unfavorable AV delay
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Optimal AV delay
Number of subjects: 12
Study: 3260641

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (non-electrically stimulated spastics)
Number of subjects: 44
Study: 5484103

Group type: EXPERIMENTAL
Intervention: High-arousal group (exposed to infantile oral objects)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low-arousal group (believed they only had to blow on whistles or pipes)
Number of subjects: 48
Study: 30915458

Group type: EXPERIMENTAL
Intervention: CAS4 (4 weeks of full feeding with cassava meal)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: CAS5 (5 weeks of full feeding with cassava meal)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: CAS6 (6 weeks of full feeding with cassava meal)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: All treatments (CAS4, CAS5, CAS6)
Number of subjects: 216
Study: 29219093

Group type: EXPERIMENTAL
Intervention: Cellphone reminder/recall intervention
Number of subjects: 595

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 595
Study: 26453108

Group type: COMPARATOR
Intervention: Intravenous acetaminophen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Strong opioids (up to 100mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Strong opioids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Step III analgesics
Number of subjects: 0
Study: 23860019

Group type: EXPERIMENTAL
Intervention: Real PKP treatment (1 treatment weekly for 5 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham PKP treatment (1 treatment weekly for 5 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 70
Study: 22102862

Group type: EXPERIMENTAL
Intervention: Masked anti-CD20 (rituximab)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Masked placebo
Number of subjects: 156
Study: 19170232

Group type: EXPERIMENTAL
Intervention: Low-dose CAF (300 mg/m(2), 30 mg/m(2), 300 x 2 mg/m(2) over 4 cycles)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Standard-dose CAF (400 mg/m(2), 40 mg/m(2), 400 x 2 mg/m(2) over 6 cycles)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: High-dose CAF (600 mg/m(2), 60 mg/m(2), 600 x 2 mg/m(2) over 4 cycles)
Number of subjects: 245
Study: 16515705

Group type: EXPERIMENTAL
Intervention: Alternating ibuprofen (10 mg/kg) and acetaminophen (15 mg/kg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Alternating ibuprofen and acetaminophen
Number of subjects: 70
Study: 15266074

Group type: EXPERIMENTAL
Intervention: Lymphocyte chromosomal translocations assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micronuclei assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPRT mutations assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apoptotic cells assay
Number of subjects: 0
Study: 11258130

Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac-sodium by short time i.v.-infusion (30 min)
Number of subjects: 59
Study: 9190982

Group type: COMPARATOR
Intervention: ip Carboplatin 400 mg/m2 Day 1 q 28 days (CBDCA)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: ip interferon‐alpha 25 x 10(6) U Day 1 + ip carboplatin 400 mg/m2 Day 2 q 28 days (CBDCA + IFN)
Number of subjects: 111
Study: 8466006

Group type: EXPERIMENTAL
Intervention: Guide wire technique
Number of subjects: 138

Group type: COMPARATOR
Intervention: Direct method
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Guide wire technique in female patients
Number of subjects: 138

Group type: COMPARATOR
Intervention: Direct technique in female patients
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Guide wire technique in male patients
Number of subjects: 138

Group type: COMPARATOR
Intervention: Direct technique in male patients
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Guide wire technique in patients with thready pulse
Number of subjects: 138
Study: 3514687

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 31
Study: 31016886

Group type: EXPERIMENTAL
Intervention: Asparagus consumption (specific number of spears not detailed)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Kinetic-pharmacodynamic model
Number of subjects: 42
Study: 29485527

Group type: EXPERIMENTAL
Intervention: Moderate to severe depressive symptoms (BDI‐II cutoff)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Socioeconomic status and quality of life
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Percentage of individuals with below target age predicted fitness
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Antidepressant use among women with moderate to severe depressive symptoms
Number of subjects: 1075
Study: 26810378

Group type: EXPERIMENTAL
Intervention: Pay for performance (P4P) incentives for community physicians
Number of subjects: 323812

Group type: COMPARATOR
Intervention: Nonincentivized community physicians
Number of subjects: 323812
Study: 25078754

Group type: EXPERIMENTAL
Intervention: Learning-centered strategy (LCS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Teaching-centered strategy (TCS)
Number of subjects: 20
Study: 22540436

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Emotion dysregulation
Number of subjects: 197
Study: 19798576

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 38
Study: 17599425

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure <120 mm Hg (more intensive goal)
Number of subjects: 4733

Group type: COMPARATOR
Intervention: Systolic blood pressure <140 mm Hg (less intensive goal)
Number of subjects: 4733
Study: 15848601

Group type: EXPERIMENTAL
Intervention: Losartan (25 to 50 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Candesartan (4 to 8 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 to 40 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no hypertension)
Number of subjects: 12
Study: 12709129

Group type: EXPERIMENTAL
Intervention: High resolution ultrasound (HRUS) scanning
Number of subjects: 20

Group type: COMPARATOR
Intervention: Photography
Number of subjects: 20
Study: 10527967

Group type: EXPERIMENTAL
Intervention: Mutational screening of testosterone 5‐alpha reductase type 1
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Mutational screening of prostaglandin F2alpha receptor
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Mutational screening of endothelin 1
Number of subjects: 23
Study: 8577020

Group type: EXPERIMENTAL
Intervention: Drinks with increasing carbohydrate content (45 to 90 g/L) at constant osmolarity (330 mOsm/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Drinks with constant carbohydrate content (60 g/L) but varying osmolarity (243 to 374 mOsm/kg)
Number of subjects: 12
Study: 1960303

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 145

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 145
Study: 6801877

Group type: EXPERIMENTAL
Intervention: Nitroglycerin administration
Number of subjects: 10
Study: 2420602

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bleomycin, vinblastine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bleomycin, etoposide, cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etoposide and cisplatin
Number of subjects: 0
Study: 31471911

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of CBT and sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30104492

Group type: EXPERIMENTAL
Intervention: Phase integral accumulation algorithm
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Randomized Hough transform (RHT) algorithm
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Unambiguous phase differences
Number of subjects: 1
Study: 27332968

Group type: EXPERIMENTAL
Intervention: 8-week Internet-based, tailored exercise program
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 24915929

Group type: COMPARATOR
Intervention: Latent Semantic Analysis (LSA) applied to picture book narratives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latent Semantic Analysis (LSA) applied to a more demanding narrative recall task
Number of subjects: 0
Study: 22832887

Group type: COMPARATOR
Intervention: Nonoperative treatment with a sling
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Operative treatment with a stainless steel 3.5‐mm reconstruction plate
Number of subjects: 60
Study: 20150572

Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Bevacizumab (both doses)
Number of subjects: 1043
Study: 18208932

Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15728051

Group type: EXPERIMENTAL
Intervention: Large volume infusion (2 mL/kg per hour fasting) of compound sodium lactate solution
Number of subjects: 80

Group type: COMPARATOR
Intervention: Small volume infusion (3 mL/kg) of compound sodium lactate solution
Number of subjects: 80
Study: 11533541

Group type: EXPERIMENTAL
Intervention: BIS monitoring (group 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No BIS monitoring (group 2)
Number of subjects: 90
Study: 9766454

Group type: EXPERIMENTAL
Intervention: Braden Scale assessment every 48 to 72 hours for 1 to 4 weeks
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Risk assessment on admission
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Ongoing assessment in SNFs and VAMCs
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Assessment at 48 to 72 hours after admission in tertiary care
Number of subjects: 843
Study: 8311374

Group type: EXPERIMENTAL
Intervention: Prepaid care in capitated health plans
Number of subjects: 800

Group type: COMPARATOR
Intervention: Fee-for-service care
Number of subjects: 800
Study: 3041358

Group type: EXPERIMENTAL
Intervention: Sandoglobulin (500 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albumin (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sandoglobulin (in vitro addition)
Number of subjects: 0
Study: 29890286

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control (Routine Care)
Number of subjects: 375
Study: 26474870

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1613
Study: 25312005

Group type: EXPERIMENTAL
Intervention: Community Development Teams (CDT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Independent county implementation strategy (IND)
Number of subjects: 51
Study: 22057836

Group type: EXPERIMENTAL
Intervention: Exercise group (3 x 20 minutes a week for 12 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 20565161

Group type: EXPERIMENTAL
Intervention: 150 min/week of moderate intensity exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 60
Study: 17956570

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bovine collagen membrane (BME)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No membrane (Control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Implant exposure
Number of subjects: 22
Study: 15997871

Group type: EXPERIMENTAL
Intervention: IL-2 plus antiretrovirals (ARV)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (ARV only)
Number of subjects: 28
Study: 12115019

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (50 g)
Number of subjects: 1479

Group type: COMPARATOR
Intervention: Supportive care only
Number of subjects: 1479
Study: 9459375

Group type: EXPERIMENTAL
Intervention: Iron supplementation for 8 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 37
Study: 9385113

Group type: EXPERIMENTAL
Intervention: Treatment under non-identifiable assumptions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted log-rank tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment effect estimation
Number of subjects: 0
Study: 2571864

Group type: EXPERIMENTAL
Intervention: Porcine insulin (50 mU/kg per hour)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Human insulin (50 mU/kg per hour)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both insulins (human and porcine)
Number of subjects: 8
Study: 354938

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Clonazepam vs Baclofen
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combination of Clonazepam and Baclofen
Number of subjects: 68
Study: 30564806

Group type: EXPERIMENTAL
Intervention: Immediate loading of dental implants with SLActive surface
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Early loading of dental implants with SLActive surface
Number of subjects: 56
Study: 29673361

Group type: EXPERIMENTAL
Intervention: SQ1 and SQ2 (Surprise Questions)
Number of subjects: 28

Group type: COMPARATOR
Intervention: SQ1 (Surprise Question 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SQ2 (Surprise Question 2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No additional information
Number of subjects: 28
Study: 26849259

Group type: EXPERIMENTAL
Intervention: Large machinery-related injuries
Number of subjects: 7420

Group type: EXPERIMENTAL
Intervention: Male gender, increasing age, state of residence, history of prior injury, increasing hours worked per week
Number of subjects: 7420
Study: 24555575

Group type: EXPERIMENTAL
Intervention: Submandibular gland transfer
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 65
Study: 23286612

Group type: EXPERIMENTAL
Intervention: Telephonic outreach and engagement within 24 hours of discharge
Number of subjects: 1994

Group type: COMPARATOR
Intervention: Delayed telephonic outreach and engagement 48 hours after discharge notification
Number of subjects: 1994
Study: 20851724

Group type: EXPERIMENTAL
Intervention: Alcohol drink preload
Number of subjects: 40

Group type: COMPARATOR
Intervention: Energy-matched control (alcohol-free juice)
Number of subjects: 40
Study: 18201432

Group type: EXPERIMENTAL
Intervention: Traditional aerosol therapy (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Abbreviated aerosol therapy with new spacer mouth mask (Group B)
Number of subjects: 30
Study: 15716985

Group type: EXPERIMENTAL
Intervention: Phenobarbital (5 mg/kg/day for first 3 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 56
Study: 12093850

Group type: EXPERIMENTAL
Intervention: Day 3 embryo transfer (after culture in human tubal fluid)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer (after culture in sequential media)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer using Irvine blastocyst medium
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer using G1.2/G2.2 medium
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer using Cook blastocyst medium
Number of subjects: 235
Study: 10069787

Group type: EXPERIMENTAL
Intervention: 10 mL/kg body weight of 0.9% saline infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion in normal subjects
Number of subjects: 10
Study: 7568536

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (individual)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marital therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 2208537

Group type: EXPERIMENTAL
Intervention: Ethyl chloride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine (0.2 ml one per cent intradermally)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No anaesthetic
Number of subjects: 120
Study: 156069

Group type: EXPERIMENTAL
Intervention: Topical application of chemotherapeutic agents (15 drugs)
Number of subjects: 41
Study: 30936583

Group type: EXPERIMENTAL
Intervention: ECMO simulations for perfusion students
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECMO simulations for non‐perfusion students
Number of subjects: 0
Study: 28294174

Group type: EXPERIMENTAL
Intervention: EPA+DHA (4 g/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 25066503

Group type: EXPERIMENTAL
Intervention: Kinematic plus VR training (KTVR)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Kinematic training (KT)
Number of subjects: 32
Study: 24497661

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT‐I)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Monitor-only waitlist control
Number of subjects: 45
Study: 22935854

Group type: EXPERIMENTAL
Intervention: Stretching program (three exercises of hamstrings stretching of 20 seconds per exercise, three sessions a week for 12 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no hamstring stretching program)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Stretching program
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 19335986

Group type: EXPERIMENTAL
Intervention: Capsule metadoxine 500mg tid po
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo 2 pillows tid po
Number of subjects: 254
Study: 18089265

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 0
Study: 15321816

Group type: EXPERIMENTAL
Intervention: AB-yogurt (10^7 colony-forming units of both Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12/mL) twice daily after a meal for 6 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Milk placebo
Number of subjects: 59
Study: 11597538

Group type: EXPERIMENTAL
Intervention: EBRT group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 9564391

Group type: EXPERIMENTAL
Intervention: Tunnelled group
Number of subjects: 213

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 213
Study: 1525604

Group type: EXPERIMENTAL
Intervention: Splenic irradiation (SI+)
Number of subjects: 239

Group type: COMPARATOR
Intervention: No splenic irradiation (SI‐)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Both SI+ and SI‐
Number of subjects: 239
Study: 4025206

Group type: EXPERIMENTAL
Intervention: Tryptophan
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tyrosine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29409289

Group type: EXPERIMENTAL
Intervention: Suture-tape augmentation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Modified Broström procedure
Number of subjects: 60
Study: 28601497

Group type: EXPERIMENTAL
Intervention: Once-monthly paliperidone palmitate (PP1M)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Daily oral antipsychotics
Number of subjects: 130
Study: 26800231

Group type: EXPERIMENTAL
Intervention: Baricitinib 8 mg
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Baricitinib 10 mg
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Baricitinib (all doses except 2 mg)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Baricitinib 8 mg and 10 mg
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Baricitinib (all doses)
Number of subjects: 271
Study: 24189107

Group type: EXPERIMENTAL
Intervention: Latent MTPs
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-MTPs
Number of subjects: 15
Study: 22451206

Group type: EXPERIMENTAL
Intervention: Inhalation of liquefied brain tissue (5 days per week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposed mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients and exposed mice
Number of subjects: 0
Study: 20637202

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a alone
Number of subjects: 1343

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a with ribavirin
Number of subjects: 1343

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1343
Study: 17444589

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg plus MTX
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Infliximab 6 mg/kg plus MTX
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 70
Study: 14725717

Group type: EXPERIMENTAL
Intervention: AIOS 24-hour
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: AIOS 1-month
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: AIOS scores
Number of subjects: 620
Study: 12411835

Group type: EXPERIMENTAL
Intervention: Sestamibi scintimammography
Number of subjects: 73

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Mammography + Sestamibi scintimammography
Number of subjects: 73
Study: 9812075

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24